You are here

PROSTAT KANSERİNDE SERUM PSA DÜZEYİ VE BİYOPSİ GLEASON SKORUNUN RADİKAL PROSTATEKTOMİ PATOLOJİSİNİ ÖNGÖRMEDEKİ DEĞERİ

THE VALUE OF PREOPERATIVE PSAAND BIOPSY GLEASON SCORE IN THE PREDICTION OF THE GLEASON SCORE OF RADICAL PROSTATECTOMY SPECIMEN

Journal Name:

Publication Year:

Keywords (Original Language):

Abstract (2. Language): 
Objective: The tumor stage, Gleason score and PSA level are known as very important parameters in the prediction of prognosis of prostate cancer. We evaluated the value of these prognostic factors in the prediction of the prognosis of prostate cancer. Materials and methods: Between February 2001 and 2008, 121 patients (36-75 yrs) who underwent radical prostatectomy due to clinically localised prostate cancer were included in the study. The demographic characteristics of the patients in addition to serum PSA level and the Gleason scores both in the neddle biopsy of the prostate and radical prostatectomy specimen were evaluated. Results: Mean PSA level and Gleason score before the operation was 9.8 ng/ml and 6.20 (4-9), respectively. Mean Gleason score of prostatectomy specimens was 6.48 (5-10). While the Gleason scores of prostatectomy and TRUS guided prostate biospy were same in 70 (%57.8) patients, there was at least 1 point difference between the Gleason scores in others. Conclusion: As a conclusion, the Gleason score of biopsy specimen was found to be different from that of radical prostatectomy specimen in almost half of the patients
Abstract (Original Language): 
Amaç: Prostat kanserinin seyrinin öngörülebilmesi için tümör evresi, Gleason skoru ve serum PSA düzeyi gibi prognostik faktörlerin bilinmesi gerekmektedir. Serum PSA düzeyi ve biyopsi Gleason skorunun radikal prostatektomi patolojisini öngörmedeki de¤erini araflt›rd›k. Gereç ve yöntem: fiubat 2001 ile 2008 tarihleri aras›nda transrektal ultrasonografi (TRUS) eflli¤inde yap›lan i¤ne biyopsisi ile klinik olarak lokalize prostat kanseri tan›s› konulan ve radikal prostatektomi operasyonu uygulanan 121 hasta (36-75) çal›flmaya dahil edildi. Tüm hastalar›n demografik özellikleri ile beraber operasyon öncesi serum total PSA düzeyleri ile preoperatif ve postoperatif Gleason skorlar› retrospektif olarak incelendi. Bulgular: Tan› s›ras›ndaki ortalama PSA düzeyi 9,8 ng/ml ve i¤ne biyopsisi spesimenlerinin ortalama Gleason skoru 6,20 (4-9) olan hastalar›n radikal prostatektomi sonras› spesimenlerin ortalama Gleason skoru 6,48 (5-10) olarak bulundu. 70 hastada (%57,8) i¤ne biyopsisindeki Gleason skoru, radikal prostatektomi spesimenindeki Gleason skoru ile eflit bulunurken, geri kalan hastalarda preoperatif ve postoperatif Gleason skorlar› aras›nda en az 1 fark bulundu. Sonuç: Hastalar›n yar›s›na yak›n k›sm›nda i¤ne biyopsisinin Gleason skoru, radikal prostatektomi Gleason skorundan farkl› bulunmufltur. Bu da i¤ne biopsisi sonucunun, ameliyat spesimenindeki skoru öngörmede yetersiz kald›- ¤›n› düflündürmektedir.
10-13

REFERENCES

References: 

1. Adolfsson J, Steineck G, Whitmore WF Jr. Recent results of management
of palpable clinically localized prostate cancer. Cancer
1993; 72: 310-322.
2. Antonopoulos IM, Arap MA, Pompeo ACL, Sarkis AS, Hayek
ORE, Danilovic A. Comparison of Gleason score of prostate biopsy
and radical prostatectomy specimen. 25th Congress of the
Societe Internationale d'Urologie (Whitfield H, ed), Singapore.
Blackwell Science 2000; 141.
3. Bostwick DG. Gleason grading of prostatic needle biopsies.
Correlation with grade in 316 matched prostatectomies. Am J
Surg Pathol 1994; 18:796-803.
4. Cancer Facts and Figures: Atlanta. American Cancer Society
1998.
5. Fernanades ET, Sundaram CP, Long R, Soltani M, Ercole CJ.
Biopsy Gleason score: how does it correlate with the final pathological
diagnosis in prostate cancer. Br J Urol 1997; 79:615-617.
6. Feyaerts A, Delree A, Lorge F, Opsomer RJ, Wese FX, Van
Cangh PJ, Draguet AP, Cosyns JP. Recurrence following radical
surgery for pros-tatic cancer. Analysis of clinical, biological and
anatomo-pathological prognostic factors. Acta Urol Belg 1997;
65:11-18.
7. Fidaner C, Eser SY, Parkin DM. First Results from Cancer Registry.
Incidence in ‹zmir in 1993-1994: first results from Izmir
Cancer Registry. Eur J Cancer 2001; 37:83-92.
8. Figler BD, Reuther AM, Dhar N, Levin H, Magi-Galluzzi C,
Zhou M, Klein EA. Preoperative PSA is still predictive of cancer
volume and grade in late PSA era. Urology 2007; 70:711-
716.
9. Fowler JE Jr, Milss SE. Operable prostatic carcinoma: correlations
among clinical stage, pathological stage, Gleason histological
score and early disease free survival. J Urol 1985; 133: 49-
52.
10. Garnett JE, Oyasu R, Grayhack JT. The accuracy of diagnostic
biopsy specimens in predicting tumor grades by Gleason’s classification
of radical prostatectomy specimens. J Urol 1984;
131:690-693.
11. Gleason DF, Mellinger GT. The Veterans Administration Cooperative
Urologic Research Group. The prediction of prognosis for
prostatic adenocarcinoma by combined histologic grading and
clinical staging. J Urol 1974; 111: 58-64.
12. Gregori A, Vieweg J, Dahm P, Paulson DF. Comparison of ultrasound-
guided biopsies and prostatectomy specimens: Predictive
accuracy of Gleason score and tumor site. Urol Int 2001; 66: 66.
13. Groll R, Fleshner NE, Sugar L, Ezer D, Klotz L. Clinical significance
of biopsy-derived primary Gleason score among radical
prostatectomy candidates with Gleason 7 tumors. Urology 2002;
59: 551.
14. Grossfeld GD, Chang JJ, Broering JM, Li YP, Lubeck DP, Flanders
SC, Carroll PR. Under staging and under grading in a contemporary
series of patients undergoing radical prostatectomy:
Result from the cancer of the prostate strategic urologic research
endeavor database. J Urol 2001; 165:851-856.
15. Köksal ‹T, Özcan F, Kad›o¤lu TC, Esen T, K›l›çaslan I, Tunç M.
Discrepancy between Gleason scores of biopsy and radical prostatectomy
specimens. Eur Urol 2000; 37:670-674.
16. Malavaud B, Villers A, Ravery V, Tollon C, Rischmann P, Charlet
JP, Plante P, Boccon-Gibod L, Sarramon JP. Role of preoperative
positive apical biopsies in the prediction of specimen-confined
prostate cancer after radikal retropubic prostatectomy: A
multi-institutional study. Eur Urol 2000; 37:281-288.
17. Noguchi M, Stamey TA, McNeal JE, Yemoto CM. Relationship
between systematic biopsies and histological features of 222 radical
prostatectomy specimens: Lack of prediction of tumor significance
for men with nonpalpable prostate cancer. J Urol 2001;
166: 104.
18. Özer G, Alt›nel M, Karatafl B, Aydo¤ G, Yaz›c›o¤lu A, Gönenç
F. Radikal prostatektomi sonras› patolojik evrenin de¤erlendirilmesinde
serbest/total PSA oran›n›n etkinli¤i. Türk Üroloji Dergisi
2003; 3: 258-263.
19. Parker SL, Tong T, Bolden S, Wingo PA. Cancer Statistics CA
46: 5, 1996.
20. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI,
Walsh PC. The use of prostate specific antigen, clinical stage and
Gleason score to predict pathological stage in men with localized
prostate cancer. J Urol 1993; 150:110-114.
21. Paulson DF. Impact of radical prostatectomy in the management
of clinically localized disease. J Urol 1994; 152: 1826-1830.
22. San Francisco IF, DeWolf WC, Rosen S, Upton M, Olumi AF.
Extended prostate needle biopsy improves concordance of Gleason
grading between prostate needle biopsy and radical prostatectomy.
J Urol 2003; 169:136-140.
23. Spires SE, Cibull ML, Wood DP Jr, Miller S, Spires SM, Banks
ER. Gleason histologic grading in prostatic carcinoma. Correlation
of 18-gauge core biopsy with prostatectomy. Arch Pathol
Lab Med 1994; 118:705-708.

Thank you for copying data from http://www.arastirmax.com